Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Rogers Foundation announces a second landmark gift, building on its $130 million gift in 2014, to sustain the Ted Rogers Centre for Heart Research in perpetuity and bring the promise of precision cardiac health to patients across Canada and globally. In 2014, the...
Ted Rogers Chair in Heart Function Outcomes Dr. Douglas Lee leads new Heart-Brain Connection $3 million IMPACT Award project
Four unique educational events in October and December
Targeting heart failure in Indigenous communities
Our funded study reveals inequitable COVID-19 rates from the start
Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world.
With scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing, in-clinic uses, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”[1]
On November 12th, the event will explore this subject with presentations from experts in the field, startup companies innovating in this space, and investors looking to invest in these new applications. The event will also be viewed via live stream.